Health · Pharma & Biotech · 4 hrs ago
Vanda says anxiety drug failed main goal in late-stage study
Vanda said its anxiety drug failed the main goal of a late-stage study.
The study was at a late stage of testing.
The drug was being studied for anxiety.
Vanda said it is putting the drug program on hold.
The study's main goal was not achieved.
The announcement gives no further details about what happens next.
Vanda Pharmaceuticals said its anxiety drug failed to meet the main goal of a late-stage study.
The company said it was putting the drug program on hold.
The report did not identify the drug or provide study results.
- Who
- Vanda Pharmaceuticals.
- What
- Its anxiety drug failed the main goal of a late-stage study, and the company put the program on hold.
- When
- October 14, 2026.
- Where
- Not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Company
- Vanda Pharmaceuticals
- Study stage
- Late-stage
- Outcome
- Failed the main goal
- Program status
- Put on hold
Follow